Omburtamab
(Anti-human B7-H3 mAb, human IgG1-Kappa; 8H9)
Catalog No.: PC-Ab1066Not For Human Use, Lab Use Only.
8H9 is an IgG1 mAb that targets B7-H3, it is broadly reactive with human solid tumors, including embryonal tumors and carcinomas. 131I-omburtamab, a monoclonal antibody called 8H9 linked to a radioactive agent called iodine 131. 8H9 attaches to B7H3 positive tumor cells in a targeted way and delivers iodine 131 to kill them. 8H9 has been successfully used for radioimmunotherapy for patients with B7-H3(+) tumors. In early phase human clinical trials, 131I-8H9 prolongs survival among high risk pat
8H9 is an IgG1 mAb that targets B7-H3, it is broadly reactive with human solid tumors, including embryonal tumors and carcinomas. 131I-omburtamab, a monoclonal antibody called 8H9 linked to a radioactive agent called iodine 131. 8H9 attaches to B7H3 positive tumor cells in a targeted way and delivers iodine 131 to kill them. 8H9 has been successfully used for radioimmunotherapy for patients with B7-H3(+) tumors. In early phase human clinical trials, 131I-8H9 prolongs survival among high risk patients with solid tumors suffering from central nervous system (CNS) metastasis.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
